ArticleBiotechnology and bioengineering2026
A Modular Nucleoside Kinase Cascade for the Synthesis of Ribonucleoside Triphosphates.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The increasing demand for affordable nucleoside 5'-triphosphates (NTPs) necessitates efficient and scalable methods of synthesis. Herein, we report standardized one-pot enzymatic cascades for the production of all canonical NTPs (ATP, CTP, GTP, UTP). Central to these cascades is the Saccharomyces cerevisiae (Saccharomyces cerevisiae UMP kinase (ScURA6), which efficiently phosphorylates AMP, CMP, and UMP. ScURA6 is inactive toward GMP, so Saccharomyces cerevisiae GMP kinase (ScGMPK) was used to synthesize GTP. NDPs were phosphorylated by Escherichia coli acetate kinase (EcAcK), using acetyl phosphate as the phosphate donor in the presence of catalytic amounts of ATP or GTP. Substrate-specific kinases were used to phosphorylate the nucleoside starting material. The resulting four cascades were optimized for flux through each step to afford the NTP product in the absence of NMP and NDP intermediates. The reactions were intensified for full conversion (≥ 93%) of 50-100 mM substrate within 60-120 min. Alternatively, a modified cascade employing the product NTP as a phosphate shuttle was established, achieving an NTP conversion of ≥ 84%. Preparative-scale syntheses (10 mL) reached up to 89% isolated yield (≥ 150 mg product), demonstrating a robust and scalable platform for NTP production. The kinases used are active with noncanonical nucleosides and nucleoside analogs, offering flexibility for broad synthetic applicability of the cascade transformations used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.